Keros Therapeutics, Inc. (KROS) closed the last trading session at $11.59, gaining 5.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

Keros Therapeutics, Inc. (KROS) has been on a downward spiral lately with significant selling pressure. After declining 39.2% over the past four weeks, the stock looks well positioned for a trend ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

Equities research analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Keros Therapeutics in a report released on Thursday, February 27th. William Blair ...

KROS opened at $11.08 on Friday. Keros Therapeutics has a fifty-two week low of $9.77 and a fifty-two week high of $73.00. The business has a 50-day moving average of $12.52 and a 200-day moving ...

In the presentation, titled “KROS 101: A Next Generation GITR agonist boosting anti-tumor T cell responses and reprogramming the tumor environment,” study authors demonstrated that KROS ...

Researchers from Cedars-Sinai Medical Center presented the preclinical efficacy of KROS-401, an IL-4/IL-13 blocking peptide that effectively reprograms macrophages in glioma models.